@newsforce.live: In a phase 1/2 trial of 61 patients with advanced pancreatic cancer, daraxonrasib combined with chemotherapy shrank or eliminated tumours in 60.7% of cases. The tumours became undetectable in about one in 12 patients, and disease progression was halted in 90.2%. Researchers said further trials are needed to assess the treatment’s safety and lasting effects before it could be considered for NHS use. Music: This Is News by Grand_Project Source: https://pixabay.com/music/electronic-this-is-news-396456/ License: Pixabay Content License https://pixabay.com/service/license-summary/ Music excerpt, volume adjusted and fade-out added. Opening sound supplied by NEWSFORCE.